287 related articles for article (PubMed ID: 2395016)
1. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
2. Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Zasadny KR; Mallette S; Mudgett EE; Wieland DM
J Nucl Biol Med (1991); 1991; 35(4):255-9. PubMed ID: 1823830
[TBL] [Abstract][Full Text] [Related]
3. [Follow-up evaluation of metastatic neuroblastoma using high dose [131I-meta]iodobenzylguanidine].
Klingebiel T; Reuland P; Feine U; Niethammer D
Nuklearmedizin; 1992 Dec; 31(6):209-12. PubMed ID: 1491958
[TBL] [Abstract][Full Text] [Related]
4. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.
Mastrangelo R; Lasorella A; Troncone L; Rufini V; Iavarone A; Riccardi R
J Nucl Biol Med (1991); 1991; 35(4):252-4. PubMed ID: 1823829
[TBL] [Abstract][Full Text] [Related]
5. 131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma.
Voûte PA; Hoefnagel CA; de Kraker J
Bull Cancer; 1988; 75(1):107-11. PubMed ID: 3359053
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma.
Matthay KK; Huberty JP; Hattner RS; Ablin AR; Engelstad BL; Zoger S; Hasegawa BH; Price D
J Nucl Biol Med (1991); 1991; 35(4):244-7. PubMed ID: 1823827
[TBL] [Abstract][Full Text] [Related]
7. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Carey JE; Zasadny KR; Zempel SA; Normolle DP
Eur J Nucl Med; 1994 Jan; 21(1):46-52. PubMed ID: 8088285
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of 131I mIBG in chemo-resistant neuroblastoma. The United Kingdom Children's Cancer Study Group (UKCCSG).
Lewis IJ; Lashford LS; Fielding S; Flower MA; Ackery D; Kemshead J
Prog Clin Biol Res; 1991; 366():463-9. PubMed ID: 2068161
[No Abstract] [Full Text] [Related]
9. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.
Parisi MT; Matthay KK; Huberty JP; Hattner RS
Radiology; 1992 Aug; 184(2):463-7. PubMed ID: 1620849
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation.
Lashford LS; Lewis IJ; Fielding SL; Flower MA; Meller S; Kemshead JT; Ackery D
J Clin Oncol; 1992 Dec; 10(12):1889-96. PubMed ID: 1453204
[TBL] [Abstract][Full Text] [Related]
12. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
13. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription.
Fielding SL; Flower MA; Ackery DM; Kemshead J; Lashford LS; Lewis IJ
Radiother Oncol; 1992 Sep; 25(1):73-6. PubMed ID: 1410594
[TBL] [Abstract][Full Text] [Related]
14. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy.
Voûte PA; Hoefnagel CA; de Kraker J; Valdes Olmos R; Bakker DJ; van de Kleij AJ
Prog Clin Biol Res; 1991; 366():439-45. PubMed ID: 2068157
[No Abstract] [Full Text] [Related]
15. Toxicity from treatment of neuroblastoma with 131I-meta-iodobenzylguanidine.
Sisson JC; Hutchinson RJ; Carey JE; Shapiro B; Johnson JW; Mallette SA; Wieland DM
Eur J Nucl Med; 1988; 14(7-8):337-40. PubMed ID: 3181182
[TBL] [Abstract][Full Text] [Related]
16. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
17. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives.
Beierwaltes WH
Med Pediatr Oncol; 1987; 15(4):188-91. PubMed ID: 3657705
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with neuroblastoma treated with 125-I MIBG.
Sisson JC; Shapiro B; Hutchinson RJ; Shulkin BL; Zempel S
Am J Clin Oncol; 1996 Apr; 19(2):144-8. PubMed ID: 8610638
[TBL] [Abstract][Full Text] [Related]
19. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
20. Preoperative [131I]metaiodobenzylguanidine therapy of neuroblastoma at diagnosis ("MIBG de novo").
Hoefnagel CA; de Kraker J; Voûte PA; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):248-51. PubMed ID: 1823828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
